Javascript must be enabled to continue!
A resource-based mechanistic framework for castration-resistant prostate cancer (CRPC)
View through CrossRef
Abstract
Cancer therapy often leads to the selective elimination of drug-sensitive cells from the tumour. This can favour the growth of cells resistant to the therapeutic agent, ultimately causing a tumour relapse. Castration-resistant prostate cancer (CRPC) is a well-characterised instance of this phenomenon. In CRPC, after systemic androgen deprivation therapy (ADT), a subset of drug-resistant cancer cells autonomously produce testosterone, thus enabling tumour regrowth. A previous theoretical study has shown that such a tumour relapse can be delayed by inhibiting the growth of drug-resistant cells using biotic competition from drug-sensitive cells. In this context, the centrality of resource dynamics to intra-tumour competition in the CRPC system indicates clear scope for the construction of theoretical models that can explicitly incorporate the underlying mechanisms of tumour ecology. In the current study, we use a modified logistic framework to model cell-cell interactions in terms of the production and consumption of resources. Our results show that steady state composition of CRPC can be understood as a composite function of the availability and utilisation efficiency of two resources-oxygen and testosterone. In particular, we show that the effect of changing resource availability or use efficiency is conditioned by their general abundance regimes. Testosterone typically functions in trace amounts and thus affects steady state behaviour of the CRPC system differently from oxygen, which is usually available at higher levels. Our data thus indicate that explicit consideration of resource dynamics can produce novel and useful mechanistic understanding of CRPC. Furthermore, such a modelling approach also incorporates variables into the system’s description that can be directly measured in a clinical context. This is therefore a promising avenue of research in cancer ecology that could lead to therapeutic approaches that are more clearly rooted in the biology of CRPC.
Highlights
Cancer growth and progression can be driven by intra-tumour interactions.
Prostate cancer cells compete among each other for resources like testosterone and oxygen.
We model these interactions using a modified logistic model with resource dynamics.
Equilibrium behaviour can be understood through resource supply and use efficiency.
Explicitly ecological models could enable better strategies for cancer control.
Title: A resource-based mechanistic framework for castration-resistant prostate cancer (CRPC)
Description:
Abstract
Cancer therapy often leads to the selective elimination of drug-sensitive cells from the tumour.
This can favour the growth of cells resistant to the therapeutic agent, ultimately causing a tumour relapse.
Castration-resistant prostate cancer (CRPC) is a well-characterised instance of this phenomenon.
In CRPC, after systemic androgen deprivation therapy (ADT), a subset of drug-resistant cancer cells autonomously produce testosterone, thus enabling tumour regrowth.
A previous theoretical study has shown that such a tumour relapse can be delayed by inhibiting the growth of drug-resistant cells using biotic competition from drug-sensitive cells.
In this context, the centrality of resource dynamics to intra-tumour competition in the CRPC system indicates clear scope for the construction of theoretical models that can explicitly incorporate the underlying mechanisms of tumour ecology.
In the current study, we use a modified logistic framework to model cell-cell interactions in terms of the production and consumption of resources.
Our results show that steady state composition of CRPC can be understood as a composite function of the availability and utilisation efficiency of two resources-oxygen and testosterone.
In particular, we show that the effect of changing resource availability or use efficiency is conditioned by their general abundance regimes.
Testosterone typically functions in trace amounts and thus affects steady state behaviour of the CRPC system differently from oxygen, which is usually available at higher levels.
Our data thus indicate that explicit consideration of resource dynamics can produce novel and useful mechanistic understanding of CRPC.
Furthermore, such a modelling approach also incorporates variables into the system’s description that can be directly measured in a clinical context.
This is therefore a promising avenue of research in cancer ecology that could lead to therapeutic approaches that are more clearly rooted in the biology of CRPC.
Highlights
Cancer growth and progression can be driven by intra-tumour interactions.
Prostate cancer cells compete among each other for resources like testosterone and oxygen.
We model these interactions using a modified logistic model with resource dynamics.
Equilibrium behaviour can be understood through resource supply and use efficiency.
Explicitly ecological models could enable better strategies for cancer control.
Related Results
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6‐mediated Axl and RON signaling
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6‐mediated Axl and RON signaling
AbstractBackgroundAndrogen deprivation therapy (ADT), or chemical castration, is the first‐line therapy for prostate cancer; however, resistance leaves few treatment options. Prost...
Abstract 1530: Elucidating the role of exogenous lipids in ferroptosis in castration resistant prostate cancer
Abstract 1530: Elucidating the role of exogenous lipids in ferroptosis in castration resistant prostate cancer
Abstract
Prostate Cancer (PCa) is the leading cause of cancer cases in U.S. men and the second leading cause of male cancer death. An advanced form of the disease, t...
Abstract SY13-03: Signal pathways in prostate cancer stem cells
Abstract SY13-03: Signal pathways in prostate cancer stem cells
Abstract
New therapeutic strategies are needed to treat prostate cancer as it progresses to the castration resistant stage following treatment with drugs to reduce a...
Abstract 693: Comparative gene signature between NEPC and CRPC transcriptomics
Abstract 693: Comparative gene signature between NEPC and CRPC transcriptomics
Abstract
Introduction:
Prostate cancer (PCa) is the most common cancer in men, with an estimated 299, 010 new cases and 32, 250 ...
Abstract 1777: OST11098, an orally available and selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer (CRPC) with next-generation hormone agents (NHAs) resistance
Abstract 1777: OST11098, an orally available and selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer (CRPC) with next-generation hormone agents (NHAs) resistance
Abstract
Next-generation hormone agents (NHAs) such as abiraterone and enzalutamide have become standard treatments for castration-resistant prostate cancer (CRPC), ...
PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer
PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer
Purpose: To evaluate the influence of nadir prostate-specific antigen (PSA) level and time to PSA nadir following androgen deprivation therapy (ADT)on disease progression of castra...
Studi Literatur Implementasi Kastrasi pada Anjing
Studi Literatur Implementasi Kastrasi pada Anjing
Castration is one of the important aspects in the management of maintain and care for animals. The purpose of this study was to determine the age of castration in small and large b...
Effectiveness of surgical castration by bilateral subcapsular orchiectomy as monotherapy for the treatment of advanced prostate cancer.
Effectiveness of surgical castration by bilateral subcapsular orchiectomy as monotherapy for the treatment of advanced prostate cancer.
Prostate cancer is the most common malignancy in men and the second cause of death due to cancer [1]. Treatment of prostate cancer has been a field of many progresses, but the disc...

